Unia Europejska - słoweński - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Unia Europejska - słoweński - EMA (European Medicines Agency)

ucb pharma sa  - certolizumab pegol - artritis, revmatoidni - imunosupresivi - revmatoidni arthritiscimzia, v kombinaciji z metotreksatom (mtx), je indicirano za:zdravljenje zmerno do hudo aktivnega revmatoidnega artritisa (ra) pri odraslih bolnikih, kadar je odziv na bolezni-spreminjanje antirheumatic drugs (dmards), vključno z mtx, je bila neustrezna. cimzia lahko podana kot monotherapy v primeru nestrpnost do mtx ali ko je nadaljeval zdravljenje z mtx je inappropriatethe zdravljenje hude, aktivne in postopno ra v odrasle, ki še niso bila obdelana z mtx ali drugih dmards. cimzia je dokazano, da zmanjša stopnjo napredovanja skupno škodo, ki se meri s rentgen in izboljšati telesno funkcijo, če bi imeli v kombinaciji z mtx. aksialni spondyloarthritis cimzia je indiciran za zdravljenje odraslih bolnikov s hudo aktivno osno spondyloarthritis, ki obsega:ankilozirajoči spondilitis (kot)odraslih s hudo aktivno ankilozirajoči spondilitis, ki so imeli nezadosten odgovor da, ali so nestrpni, da nesteroidna protivnetna zdravila (nesteroidnih protivnetnih zdravil). aksialni spondyloarthritis brez

Unia Europejska - słoweński - EMA (European Medicines Agency)

ratiopharm gmbh - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminiki za sistemsko zdravljenje, - desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician.

Unia Europejska - słoweński - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukemija, dlakasta celica - antineoplastična sredstva - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Unia Europejska - słoweński - EMA (European Medicines Agency)

amarin pharmaceuticals ireland limited - icosapent ethyl - dislipidemije - sredstva za spreminjanje lipidov - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Unia Europejska - słoweński - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastična sredstva - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Unia Europejska - słoweński - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapenem natrij - bakterijske okužbe - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 in 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Unia Europejska - słoweński - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imunosupresivi - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Unia Europejska - słoweński - EMA (European Medicines Agency)

extrovis eu ltd. - lakosamid - epilepsija - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Unia Europejska - słoweński - EMA (European Medicines Agency)

intervet international b.v - fluralaner - ectoparasiticides za sistemsko uporabo, isoxazolines - dogs; cats - psi:- za zdravljenje klopi in bolh infestations;izdelek se lahko uporablja tudi kot del zdravljenja strategije za nadzor bolh alergija, dermatitis (muha). - za zdravljenje demodicosis zaradi demodex canis;- za zdravljenje sarcoptic mange (sarcoptes scabiei var. canis) okužbe. - for reduction of the risk of infection with babesia canis canis via transmission by dermacentor reticulatus. [chewable tablets only]cats:- for the treatment of tick and flea infestations;the product can be used as part of a treatment strategy for the control of flea allergy dermatitis (fad). - za zdravljenje infestations z uho pršic (otodectes cynotis).